Biolevate Secured €30 Million in Series A Funding
The agentic AI platform for life sciences will use the new capital to expand its operations and open a Boston office.
Updated on Sept. 22, 2026 in Artificial Intelligence
Live Poll
Do you trust AI automation to handle regulatory and safety-critical tasks in the healthcare industry?
Biolevate has raised €30 million in a Series A funding round co-led by RAISE France and Orange Ventures. The company plans to use the capital to support international growth and establish a new office in Boston.
Why it matters
The investment aims to accelerate the deployment of the company's agentic AI platform, which automates complex life sciences workflows. By scaling its technology, Biolevate seeks to address bottlenecks in regulatory intelligence and systematic literature reviews.
The firm currently serves more than a dozen enterprise customers and has filed two patent applications in Europe. Its platform supports up to 100,000 concurrent agents while delivering an 80 per cent efficiency gain in regulatory intelligence tasks.
The players
Biolevate
This company provides an agentic AI platform designed for life sciences workflows.
RAISE France
This investment group co-led the company's recent Series A funding round.
Orange Ventures
This venture capital arm co-led the investment round to support the firm's growth.
The details
Biolevate's platform automates auditable workflows by keeping artificial intelligence outputs grounded in source evidence. The company has demonstrated significant operational improvements, including accelerating systematic literature reviews sixteenfold.
Timeline
Biolevate raised its seed round in 2024.
The Series A funding announcement was made on September 22, 2026.
The company expects to double its workforce over the next 12 months.
The Tech Race
Biolevate's focus on specialized agentic AI signals a transition toward high-reliability systems capable of managing complex, auditable enterprise tasks. This development places the startup in direct competition with legacy software providers attempting to modernize clinical and regulatory workflows.
For employees in the life sciences sector, the expansion of this platform could eventually translate to faster access to processed regulatory data and automated literature reviews. Clients may also see improved technical support as the company doubles its workforce in the coming year.
The takeaway
The move into the U.S. market via a Boston office underscores the company's strategy to capture global enterprise market share. Investors are increasingly prioritizing platforms that can demonstrate quantifiable efficiency gains rather than just general generative capabilities.
Further reading
For more on how new technologies are reshaping enterprise workflows, visit Artificial Intelligence.
Live Poll
Do you trust AI automation to handle regulatory and safety-critical tasks in the healthcare industry?
